It is well known that most GBA variants reduce GCase activity (Gegg et al., 2012), and GBA-PD may have a burden of iPD and demonstrated decreased CSF levels of total α-Syn compared with non-carriers in other cross-sectional studies (Lerche et al., 2021). This evidence concerns the gene GBA1 and Parkinson disease.